New drug combo aims to boost stroke recovery
NCT ID NCT07026318
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether adding the drug tirofiban after a standard clot-removal procedure helps people recover better from a severe stroke caused by a blocked artery. About 716 adults will receive either tirofiban or a placebo right after the procedure. The main goal is to see if more people achieve functional independence (able to care for themselves) three months later, while also checking for any increased risk of brain bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tirofiban
What this could lead to
If successful, adding tirofiban after clot removal could become a standard treatment to improve functional recovery after a stroke.
What could go wrong
This is a mid-stage trial, so results are not yet proven. The main risk is increased bleeding in the brain, which the study is carefully monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anzhen Hospital Affiliated to Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 101118, China